{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:09:52Z","timestamp":1790402992094,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Linezolid is a synthetic oxazolydinone active against multi-resistant Gram-positive cocci that inhibits proteins synthesis by interacting with the 50S ribosomal subunit. Although linezolid-resistant strains are infrequent, several outbreaks have been recently described, associated with prolonged treatment with the antibiotic. As an alternative to monotherapy, the combination of different antibiotics is a commonly used option to prevent the selection of resistant strains. In this work, we evaluated combinations of linezolid with classic and new aminoglycosides (amikacin, gentamicin and plazomicin), carbapenems (doripenem, imipenem and meropenem) and fosfomycin on several linezolid- and methicillin-resistant strains of Staphylococcus aureus and S. epidermidis, isolated in a hospital intensive care unit in Madrid, Spain. Using checkerboard and time-kill assays, interesting synergistic effects were encountered for the combination of linezolid with imipenem in all the staphylococcal strains, and for linezolid\u2013doripenem in S.epidermidis isolates. The combination of plazomicin seemed to also have a good synergistic or partially synergistic activity against most of the isolates. None of the combinations assayed showed an antagonistic effect.<\/jats:p>","DOI":"10.3390\/antibiotics9080496","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T05:07:23Z","timestamp":1597036043000},"page":"496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains"],"prefix":"10.3390","volume":"9","author":[{"given":"Mar\u00eda-Jos\u00e9","family":"Valderrama","sequence":"first","affiliation":[{"name":"Departamento de Gen\u00e9tica, Fisiolog\u00eda y Microbiolog\u00eda, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ic\u00edar","family":"Rodr\u00edguez-Avial","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Baos","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodr\u00edguez-Avial","sequence":"additional","affiliation":[{"name":"Departamento de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Culebras","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"},{"name":"Departamento de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijantimicag.2015.07.022","article-title":"Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections","volume":"46","author":"Decousser","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_2","unstructured":"European Centre for Disease Prevention and Control (2018). Surveillance of Antimicrobial Resistance in Europe\u2014Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin vusceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","first-page":"922","article-title":"MRSA: Treating people with infection","volume":"2","author":"Rae","year":"2016","journal-title":"BMJ Clin. Evid."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkt541","article-title":"Zyvox annual appraisal of potency and spectrum (ZAAPS) program: Report of linezolid activity over 9 years (2004\u201312)","volume":"69","author":"Mendes","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2003.07.012","article-title":"Effects of linezolid on staphylococcal adherence versus time of treatment","volume":"23","author":"Pagano","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/CMR.1.2.139","article-title":"Clinical antibiotic combinations: Should they be tested?","volume":"1","author":"Eliopoulos","year":"1988","journal-title":"Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/IDR.S175978","article-title":"In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus","volume":"11","author":"Chen","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40360-019-0305-y","article-title":"A study on combination of daptomycin with selected antimicrobial agents: In vitro synergistic effect of MIC value of 1mg\/L against MRSA strains","volume":"20","author":"Lee","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"Morales","year":"2010","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bjid.2020.01.003","article-title":"Coagulase-negative staphylococci: A 20-year study on the antimicrobial resistance profile of blood culture isolates from a teaching hospital","volume":"24","author":"Cataneli","year":"2020","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_16","first-page":"e00609","article-title":"Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important Gram positive cocci in the United States from the LEADER Surveillance Program (2011 to 2015)","volume":"61","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/650574","article-title":"Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus","volume":"50","author":"Morales","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.46.10.3334-3336.2002","article-title":"Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis","volume":"46","author":"Marshall","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/JCM.00098-13","article-title":"Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in Italy","volume":"51","author":"Campanille","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.diagmicrobio.2018.01.027","article-title":"Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium","volume":"91","author":"Smith","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.diagmicrobio.2013.04.002","article-title":"Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus","volume":"76","author":"Baos","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrmicro2182","article-title":"Staphylococcus epidermidis\u2014The \u201caccidental\u201d pathogen","volume":"7","author":"Otto","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/phar.2203","article-title":"Plazomicin: A next-generation aminoglycoside","volume":"39","author":"Shaeer","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkq065","article-title":"Dissemination of two international linezolid-resistant Staphylococcus epidermidis clones in Greek hospitals","volume":"65","author":"Liakopoulos","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","first-page":"252","article-title":"In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus","volume":"19","author":"Sauquillo","year":"2006","journal-title":"Rev. Esp. Quimioterap."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/AAC.47.1.418-420.2003","article-title":"In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus","volume":"47","author":"Grohs","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijantimicag.2008.11.002","article-title":"In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections","volume":"33","author":"Kuli","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"Rybak","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2018.12.007","article-title":"Analysis of synergy between beta-lactams and anti-methicillinresistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action","volume":"25","author":"Ono","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1128\/AAC.00237-09","article-title":"in vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus","volume":"53","author":"Singh","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijantimicag.2017.01.039","article-title":"In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: Potency of plazomicin alone and in combination with other agents","volume":"50","author":"Lopez","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1128\/AAC.01350-09","article-title":"Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay","volume":"54","author":"Lin","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/jac\/48.2.209","article-title":"In vitro activity of fosfomycin in combination with various antistaphylococcal substances","volume":"48","author":"Grif","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.01501-05","article-title":"In vitro and in vivo assessment of linezolid combined with ertapenem: A highly synergistic combination against methicillin-resistant Staphylococcus aureus","volume":"50","author":"Jacqueline","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10096-010-1058-0","article-title":"Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin","volume":"30","author":"Ribes","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10096-010-1007-y","article-title":"In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides","volume":"29","author":"Ribes","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ja.2014.5","article-title":"In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus","volume":"67","author":"Falagas","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2018.07.015","article-title":"Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates","volume":"93","author":"Campanile","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_39","first-page":"168","article-title":"Actividad in vitro de linezolid, moxifloxacino, levofloxacino, clindamicina y rifampicina, solos o en combinaci\u00f3n, frente a Staphylococcus aureus y Staphylococcus epidermidis","volume":"18","author":"Soriano","year":"2005","journal-title":"Rev. Esp. Quimioterap."},{"key":"ref_40","unstructured":"Wadhwa, R.R., and Cascella, M. (2020). Steady State Concentration, StatPearls Publishing LLC."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1128\/AAC.00269-09","article-title":"Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis","volume":"53","author":"Foweraker","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijantimicag.2018.01.014","article-title":"Evaluation of linezolid or trimethoprim\/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm","volume":"51","author":"Murillo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","unstructured":"EUCAST. The European Committee on Antimicrobial Susceptibility Testing (2020). Routine and Extended Internal Quality Control for MIC Determination and Disk Diffusion as Recommended by EUCAST, EUCAST. Version 10.0."},{"key":"ref_44","unstructured":"CLSI (2012). M07-A9: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Clinical and Laboratory Standards Institute. Approved Standard\u2014Ninth Edition."},{"key":"ref_45","unstructured":"FDA (2020, June 04). Antibacterial Susceptibility Test Interpretive Criteria, Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"ref_46","unstructured":"CLSI (1998). M26-A: Methods for Determining Bactericidal Activity of Antimicrobial Agents, Clinical Laboratory Standard Institute. Approved Guideline."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1128\/AAC.01099-06","article-title":"In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii","volume":"51","author":"Scheetz","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0213-005X(08)72695-8","article-title":"Recomendaciones para la monitorizaci\u00f3n de antibi\u00f3ticos en pacientes cr\u00edticos ingresados en UCI","volume":"26","author":"Olaeche","year":"2008","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1128\/AAC.00741-13","article-title":"Evaluation of double- and triple-antibiotic combinations for VIM and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments","volume":"58","author":"Hickman","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/8\/496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:58:25Z","timestamp":1760176705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/8\/496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,9]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["antibiotics9080496"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9080496","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,9]]}}}